ArticleAnnals of clinical and translational neurology2023
A blood biomarker test for brain amyloid impacts the clinical evaluation of cognitive impairment.
Article in Annals of clinical and translational neurology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05477056 (Quality Improvement Survey I.0), which is not on this map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Quality Improvement Survey I.0: A Retrospective Data Analysis of Clinician Survey Responses Following the Utilization of the PrecivityADTM Blood Test for the Detection of Alzheimer's Disease Pathology (QUIP I)
Who cites it
24 citing papers in PubMed, 33 citations in OpenAlex.
- Earlier Disclosure of Blood-Based Biomarkers, Diagnostic Certainty, and Clinical Management: A Randomized Clinical Trial.JAMA neurology · 2026Article
- Plasma Aβ42/Aβ40 determined by mass spectrometry is associated with longitudinal changes in amyloid accumulation, brain atrophy, and conversion to mild cognitive impairment due to Alzheimer's disease in individuals with subjective cognitive decline: 5-year follow-up of the FACEHBI cohort.The journal of prevention of Alzheimer's disease · 2026Article
- Concurrent detection of cognitive impairment and amyloid positivity with a multimodal machine learning-enabled digital cognitive assessment.Alzheimer's research & therapy · 2025Article
- Letter to the editor regarding "beyond memory: leveraging CSF biomarkers in all MCI patients ahead of anti-amyloid therapies".Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2025Article
- Circulating Biomarkers for the Early Diagnosis of Alzheimer's Disease.International journal of molecular sciences · 2025Review
- Developing non-invasive molecular markers for early risk assessment of Alzheimer's disease.Biomarkers in neuropsychiatry · 2025Article
- Diagnostic and discriminative accuracy of plasma phosphorylated tau 217 for symptomatic Alzheimer's disease in a Chinese cohort.The journal of prevention of Alzheimer's disease · 2025Article
- Alzheimer's disease blood-based biomarker testing: A stakeholder-informed assessment of coverage considerations.Journal of Alzheimer's disease : JAD · 2025Review
- Diagnostic journey and management of patients with mild cognitive impairment and Alzheimer's disease dementia: A multinational, real-world survey.Journal of Alzheimer's disease : JAD · 2025Article
- Cutting through the noise: A narrative review of Alzheimer's disease plasma biomarkers for routine clinical use.The journal of prevention of Alzheimer's disease · 2025Review
- Considerations in the clinical use of amyloid PET and CSF biomarkers for Alzheimer's disease.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025Review
- Accuracy of plasma biomarkers to detect Alzheimer's disease proteinopathy prior to dementia.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025Article
- Clinical Utility of an Alzheimer's Disease Blood Test Among Cognitively Impaired Patients: Results from the Quality Improvement PrecivityAD2 (QUIP II) Clinician Survey Study.Diagnostics (Basel, Switzerland) · 2025Article
- Independent validation of the PrecivityAD2™ blood test to identify presence or absence of brain amyloid pathology in individuals with cognitive impairment.NPJ dementia · 2025Article
- PrecivityAD2™ Blood Test: Analytical Validation of an LC-MS/MS Assay for Quantifying Plasma Phospho-tau217 and Non-Phospho-tau217 Peptide Concentrations That Are Used with Plasma Amyloid-β42/40 in a Multianalyte Assay with Algorithmic Analysis for Detecting Brain Amyloid Pathology.Diagnostics (Basel, Switzerland) · 2024Article
- Revised criteria for diagnosis and staging of Alzheimer's disease: Alzheimer's Association Workgroup.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2024Article
- Baseline levels and longitudinal changes in plasma Aβ42/40 among Black and white individuals.Nature communications · 2024Article
- Use of a Blood Biomarker Test Improves Economic Utility in the Evaluation of Older Patients Presenting with Cognitive Impairment.Population health management · 2024Article
- Highly accurate blood test for Alzheimer's disease is similar or superior to clinical cerebrospinal fluid tests.Nature medicine · 2024Article
- Biological variation estimates of Alzheimer's disease plasma biomarkers in healthy individuals.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors at 9 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveThe objective of this study was to examine clinicians' patient selection and result interpretation of a clinically validated mass spectrometry test measuring amyloid beta and ApoE blood biomarkers combined with patient age (PrecivityAD® blood test) in symptomatic patients evaluated for Alzheimer's disease (AD) or other causes of cognitive decline.
methodsThe Quality Improvement and Clinical Utility PrecivityAD Clinician Survey (QUIP I, ClinicalTrials.gov Identifier: NCT05477056) was a prospective, single-arm cohort study among 366 patients evaluated by neurologists and other cognitive specialists. Participants underwent blood biomarker testing and received an amyloid probability score (APS), indicating the likelihood of a positive result on an amyloid positron emission tomography (PET) scan. The primary study outcomes were appropriateness of patient selection as well as result interpretation associated with PrecivityAD blood testing.
resultsA 95% (347/366) concordance rate was noted between clinicians' patient selection and the test's intended use criteria. In the final analysis including these 347 patients (median age 75 years, 56% women), prespecified test result categories incorporated 133 (38%) low APS, 162 (47%) high APS, and 52 (15%) intermediate APS patients. Clinicians' pretest and posttest AD diagnosis probability changed from 58% to 23% in low APS patients and 71% to 89% in high APS patients (p < 0.0001). Anti-AD drug therapy decreased by 46% in low APS patients (p < 0.0001) and increased by 57% in high APS patients (p < 0.0001).
interpretationThese findings demonstrate the clinical utility of the PrecivityAD blood test in clinical care and may have added relevance as new AD therapies are introduced.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.